Organon (OGN) Completes Acquisition of Dermavant Oct 28, 2024 09:25AM
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% Oct 28, 2024 09:25AM
Organon (OGN) to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1% Sep 18, 2024 07:30AM
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% Sep 18, 2024 07:30AM
Roivant(ROIV) Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1% May 16, 2023 07:02AM


May 16, 2023 07:00AM Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Mar 15, 2023 07:46AM Roivant Sciences (ROIV) Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Mar 15, 2023 07:45AM Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Mar 15, 2023 07:45AM Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Mar 15, 2023 07:45AM Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Dec 1, 2022 08:05AM Roivant Sciences (ROIV) and Pfizer (PFE) Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Dec 1, 2022 08:00AM Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Dec 1, 2022 08:00AM Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Jun 28, 2022 06:00AM Roivant (ROIV) and Pfizer (PFE) Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
May 24, 2022 06:01AM Roivant Sciences' (ROIV) Dermavant Announces FDA Approval of VTAMA Cream
May 24, 2022 06:00AM FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
May 24, 2022 06:00AM FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
May 24, 2022 06:00AM FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
May 16, 2022 07:00AM Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)
Mar 25, 2022 08:01AM Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
Dec 16, 2021 10:00AM Virtual Reality Startup Nanome Announces Largest Deployment to Date
Oct 29, 2021 07:52AM Roivant Discovery Announces 2021 Open Science Fellows